NCT00484276 (NGR010) is a Phase 2 clinical trial of NGR-hTNF in Malignant Pleural Mesothelioma, sponsored by AGC Biologics S.p.A..

Who is sponsoring NCT00484276?

NCT00484276 is sponsored by AGC Biologics S.p.A..

What drugs are being tested in NCT00484276?

Interventions in NCT00484276: NGR-hTNF.

What condition does NCT00484276 study?

NCT00484276 studies Malignant Pleural Mesothelioma.

Is NCT00484276 still recruiting?

NCT00484276 is currently completed. Last updated 14 January 2019.

Last reviewed 2019-01-14 · How we verify

NCT00484276: NGR010

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen

Completed Phase 2 Last updated 14 January 2019

What this trial tests

Phase 2 trial testing NGR-hTNF in Malignant Pleural Mesothelioma in 57 participants. Completed in 1 March 2013.

Timeline

1 May 2007

Primary endpoint
1 March 2013

1 March 2013

Quick facts

Lead sponsor	AGC Biologics S.p.A.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	1 May 2007
Primary completion	1 March 2013
Estimated completion	1 March 2013
Sites	4 locations across Italy

Drugs / interventions tested

NGR-hTNF — full drug profile →

Conditions studied

Malignant Pleural Mesothelioma — all drugs for Malignant Pleural Mesothelioma →

Sponsor

AGC Biologics S.p.A. — full company profile →

Who can join

18 and older, any sex, with Malignant Pleural Mesothelioma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Antitumor activity defined as progression free survival (PFS)
Time frame: during the study
Defined as the time from the date of randomization until disease progression, or death

Sponsor's own description

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide-Drug Conjugates: A New Hope for Cancer Management.
Chavda VP, Solanki HK, Davidson M, Apostolopoulos V, et al · · 2022 · cited 59× · PMID 36364057 · DOI 10.3390/molecules27217232
Vascular Disruption Therapy as a New Strategy for Cancer Treatment.
Gómez-Escudero J, Berlana-Galán P, Guerra-Paes E, Torre-Cea I, et al · · 2025 · cited 1× · PMID 41155375 · DOI 10.3390/ijms262010085
Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications.
Tan R, Yang Z, Xie J, Wu Z, et al · · 2026 · cited 1× · PMID 40033748 · DOI 10.1097/cm9.0000000000003438

Verify or expand the search:

Other trials of NGR-hTNF

Trials testing the same drug.

NCT03536039 — RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor · Phase 2 · completed
NCT00483509 — Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma · Phase 2 · completed
NCT00305084 — Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors · Phase 1 · completed

Other recruiting trials for Malignant Pleural Mesothelioma

Currently open trials in the same condition.

NCT05655078 — Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma · NA · recruiting
NCT06318286 — Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma · Phase 2 · recruiting
NCT04400539 — The IMmunotherapy Pleural 5-ALA PDT · Phase 2 · recruiting

Other AGC Biologics S.p.A. trials

Trials by the same sponsor.

NCT04097301 — Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma · Phase 1, PHASE2 · terminated
NCT00914628 — Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia · Phase 3 · terminated
NCT00483509 — Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma · Phase 2 · completed
NCT00305084 — Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00484276 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AGC Biologics S.p.A.
Last refreshed: 14 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00484276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing